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aTATE-OF-THE-ART PAPER905HF With Normal Ejection Fractionicha T. Maeder, David M. Kaye
t is estimated that approximately 50% of the heart failure (HF) population has a normal left
entricular ejection fraction, a complex broadly referred to as heart failure with normal left
entricular ejection fraction (HFNEF). Typically, these patients are presumed to represent a
omogenous population, but more detailed studies indicate that HFNEF patients are a very
eterogeneous group, with several different pathophysiologic mechanisms. Maeder and Kaye
ummarize and critically analyze available data on the pathophysiology of HFNEF and review
recently developed diagnostic algorithm. The utility of commonly applied echocardiographic
ndexes and serum biomarkers are also evaluated, along with a discussion of potential future
herapeutic directions.CLINICAL
RESEARCHNTERVENTIONAL CARDIOLOGY919Less Restenosis With PES Compared With BMS in Vein GraftsEditorial Commentmmanouil S. Brilakis, Christopher Lichtenwalter, James A. de Lemos, Michele Roesle, Owen Obel,
onald Haagen, Bilal Saeed, Chiranjeevi Gadiparthi, Joseph K. Bissett, Rajesh Sachdeva, Vassilios V. Voudris,
anagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis Fasseas, Peter Berger, Subhash Banerjee
he optimal stenting regimen for the treatment of saphenous vein graft (SVG) lesions is
nclear; the only previously published, prospective, randomized trial compared bare-metal
tenting (BMS) to sirolimus-eluting stenting (SES). SES had lower angiographic restenosis at
months but higher mortality. Brilakis and colleagues randomized 80 patients with SVG
esions to either a paclitaxel-eluting stent (PES) or BMS. The primary end point was binary
estenosis at 12 months, which occurred in 51% of the BMS-treated lesions versus 9% of the
ES-treated lesions (relative risk: 0.18). There were also strong trends favoring PES for target
essel revascularization and myocardial infarction. In SVG lesions, PES may reduce
ngiographic restenosis and target vessel failure compared with BMS.(continued on page A-25)
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aRP AND CAD931Implications of the JUPITER Studyrin D. Michos, Roger S. Blumenthal
osuvastatin therapy in the JUPITER (Justification for the Use of Statins in Primary
revention: An Intervention Trial Evaluating Rosuvastatin) study reduced cardiovascular
vents among adults (men age 50 years and women age 60 years) with low-density
ipoprotein cholesterol (LDL-C) 130 mg/dl and high-sensitivity C-reactive protein
hsCRP) 2 mg/l. Michos and Blumenthal used data from the National Health And
utrition Examination Survey to estimate how many Americans would meet the inclusion
riteria for the JUPITER study and thus be recommended to take a statin now, whereas
reviously no statin was deemed necessary. They estimate that there are 3.9 million men and
.6 million women who do not have diabetes or coronary heart disease and meet the
nclusion criteria from the JUPITER study, which greatly expands the pool of adults meriting
onsideration for statin therapy.SYCHOLOGICAL FACTORS AND CAD936Meta-Analysis Confirms Link Between Anger and CHDEditorial Comment
Johan Denollet,oichi Chida, Andrew Steptoe
hida and Steptoe conducted a meta-analysis to explore and quantify the association between
nger and hostility and coronary heart disease (CHD). There were 25 studies investigating
HD outcomes in initially healthy populations and 20 studies of samples with existing
HD. Anger and hostility were associated with increased CHD events in the healthy
opulation studies (combined hazard ratio [HR]: 1.2) and with poor prognosis in the CHD
opulation studies (HR: 1.2). The effect of anger and hostility on CHD was greater in men
han in women. These results suggest that anger and hostility are risk factors for CHD and
uggests that psychological management may be considered for CHD prevention in
ppropriate patients.(continued on page A-28)
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sSYCHOLOGICAL FACTORS AND CAD950Depression Linked to CHD, Antidepressants to SCDEditorial Comment
Sanjiv M. Narayan,illiam Whang, Laura D. Kubzansky, Ichiro Kawachi, Kathryn M. Rexrode, Candyce H. Kroenke,
obert J. Glynn, Hasan Garan, Christine M. Albert
hang and colleagues used data from the Nurses’ Health Study to examine the relationship
etween depressive symptoms and coronary heart disease (CHD). Depressive symptoms were
ssessed with the Mental Health Index (MHI-5). Primary end points included sudden
ardiac death (SCD) and fatal CHD. Approximately 8% of subjects had MHI-5 scores 53,
hich indicates depression. Low MHI-5 scores were associated with an increased risk of
HD, with a hazard ratio of 1.5 after controlling for other risk factors. The risk of SCD was
.3 times greater in subjects who took antidepressants, which seemed to be a stronger risk
redictor than low MHI-5 scores. In this cohort of women, depression was a risk factor for
HD and SCD; this risk may be related to the use of antidepressant medication.IGH-DENSITY LIPOPROTEIN962Reconstituted HDL Provides Anti-Inflammatory Effectsanjay Patel, Brian G. Drew, Shirley Nakhla, Stephen J. Duffy, Andrew J. Murphy, Phillip J. Barter,
erry-Anne Rye, Jaye-Chin-Dusting, Anh Hoang, Dmitri Sviridov, David S. Celermajer,
ronwyn A. Kingwell
atel and colleagues investigated the anti-inflammatory effects of reconstituted high-density
ipoprotein (rHDL), which consists of apolipoprotein (apo) A-I isolated from human plasma
nd phosphatidylcholine from soy beans. Thirteen subjects with type 2 diabetes mellitus
eceived either rHDL (80 mg/kg of apoA-I) or placebo. Both 4 and 72 h post-rHDL
nfusion, the anti-inflammatory properties of isolated HDL were increased. The capacity of
lasma to receive cholesterol from macrophages also increased. rHDL infusions have
ignificant, potentially atheroprotective effects in individuals with diabetes.
